Objectives The randomized comparison of deferasirox to deferoxamine for myocardial iron
removal in patients with transfusion‐dependent anemias (CORDELIA) gave the opportunity …

The benefits of both transfusion and chelation when used together are well established for
transfusion-dependent thalassemias (TDTs). With the advent of newer chelation regimens …

Transfusional iron overload represents a substantial challenge in the management of
patients with sickle cell disease (SCD) who receive chronic or episodic red blood cell …

Background Cardiomyopathic manifestations induced by continuous blood transfusion are
the leading cause of death among patients with thalassemia major (TM). Despite …

Thalassemia is a genetic disease characterized by iron overload which is a major
detrimental factor contributing to mortality and organ damage. The hepcidin secreted by liver …

Cardiosiderosis is a leading cause of mortality in transfusion-dependent thalassemias.
Plasma non-transferrin-bound iron and its redox-active component, labile plasma iron, are …

Background Cardiac iron toxicity is the leading cause of death among β-halassaemia major
(TM) patients. Once heart failure becomes overt, it is difficult to reverse. Objectives To …

The consequence of regular blood transfusion in patients with thalassemia major (TM) is
iron overload. Herein, we report the long-term impact of chelation on liver iron concentration …

Thalassemia is a common genetic disorder in Tunisia. Early iron concentration assessment
is a crucial and challenging issue. Most of annual deaths due to iron overload occurred in …

Iron overload is the major cause of morbidity and mortality in transfusion dependent β-
thalassemia major patients. There is a sophisticated balance of body iron metabolism of …